Market Cap 46.64M
Revenue (ttm) 3.29M
Net Income (ttm) -15.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -465.65%
Debt to Equity Ratio 0.00
Volume 954,500
Avg Vol 1,191,774
Day's Range N/A - N/A
Shares Out 68.70M
Stochastic %K 36%
Beta 0.28
Analysts Strong Sell
Price Target $3.05

Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 4 623 0333
Fax: 972 4 623 0222
Address:
7 Ha’Eshel Street, PO Box 3163, Caesarea, Israel
SuperBusa
SuperBusa Dec. 5 at 6:41 PM
0 · Reply
Joe_088
Joe_088 Dec. 5 at 3:14 PM
$ICCM Shareholders to vote on governance changes. Something cooking here.
0 · Reply
thechad369
thechad369 Dec. 5 at 2:42 PM
$ICCM this is still buyout or bust, the news this morning only aides being a viable buyout candidate
0 · Reply
moneygrabber55
moneygrabber55 Dec. 5 at 2:06 PM
$ICCM will this run today?
0 · Reply
Planetpaprika
Planetpaprika Dec. 5 at 1:52 PM
$ICCM today announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled "Cryogen Flow Control" which relates to its next-generation XSense™ cryoablation system and probes. A patent for this invention has been granted in Japan and is currently pending approval in the European Union, the U.S., and other major markets. "We believe IceCure's commitment to technology innovation and our drive to make a significant impact on patient outcomes has resulted in our intellectual property portfolio in cryoablation reaching 55 patents granted and allowed across the globe," said Eyal Shamir, IceCure's Chief Executive Officer. "Our cryoablation systems and probes already have regulatory approval in China for indications including breast cancer, and we continue to innovate next-generation liquid nitrogen-based systems including XSense™ to further improve patient outcomes."
2 · Reply
Joe_088
Joe_088 Dec. 5 at 1:33 PM
$ICCM good news
1 · Reply
MrTicker
MrTicker Dec. 5 at 1:31 PM
$ICCM https://www.prnewswire.com/news-releases/icecure-receives-notice-of-patent-allowance-in-china-for-a-novel-cryogen-flow-control-to-optimize-patient-cryoablation-outcomes-302633981.html
0 · Reply
MrTicker
MrTicker Dec. 5 at 1:31 PM
$ICCM IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes PR NEWSWIRE 7:30 AM ET 12/5/2025
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 5 at 1:03 PM
🚀 New Signal ✅ 💊 $ICCM 🗓️ Dec 5, 2025 💵 Entry: $0.6910 🎯 Target (Opt.): $0.8212 (+18.84%) 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
BinaryLogic
BinaryLogic Dec. 5 at 11:35 AM
$ICCM [Again]
0 · Reply
Latest News on ICCM
IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript

Nov 19, 2025, 12:53 PM EST - 16 days ago

IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript


IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 9, 2025, 8:30 AM EDT - 2 months ago

IceCure Medical to Attend the 2025 Maxim Growth Summit


IceCure Medical Ltd - Special Call

Oct 6, 2025, 11:25 AM EDT - 2 months ago

IceCure Medical Ltd - Special Call


IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 1:08 PM EDT - 4 months ago

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript


IceCure Announces Commencement of Rights Offering

Jul 10, 2025, 8:00 AM EDT - 5 months ago

IceCure Announces Commencement of Rights Offering


IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

May 28, 2025, 4:26 PM EDT - 6 months ago

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript


IceCure Medical Reports First Quarter 2025 Financial Results

May 28, 2025, 8:30 AM EDT - 6 months ago

IceCure Medical Reports First Quarter 2025 Financial Results


IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 1:45 PM EDT - 9 months ago

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript


SuperBusa
SuperBusa Dec. 5 at 6:41 PM
0 · Reply
Joe_088
Joe_088 Dec. 5 at 3:14 PM
$ICCM Shareholders to vote on governance changes. Something cooking here.
0 · Reply
thechad369
thechad369 Dec. 5 at 2:42 PM
$ICCM this is still buyout or bust, the news this morning only aides being a viable buyout candidate
0 · Reply
moneygrabber55
moneygrabber55 Dec. 5 at 2:06 PM
$ICCM will this run today?
0 · Reply
Planetpaprika
Planetpaprika Dec. 5 at 1:52 PM
$ICCM today announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled "Cryogen Flow Control" which relates to its next-generation XSense™ cryoablation system and probes. A patent for this invention has been granted in Japan and is currently pending approval in the European Union, the U.S., and other major markets. "We believe IceCure's commitment to technology innovation and our drive to make a significant impact on patient outcomes has resulted in our intellectual property portfolio in cryoablation reaching 55 patents granted and allowed across the globe," said Eyal Shamir, IceCure's Chief Executive Officer. "Our cryoablation systems and probes already have regulatory approval in China for indications including breast cancer, and we continue to innovate next-generation liquid nitrogen-based systems including XSense™ to further improve patient outcomes."
2 · Reply
Joe_088
Joe_088 Dec. 5 at 1:33 PM
$ICCM good news
1 · Reply
MrTicker
MrTicker Dec. 5 at 1:31 PM
$ICCM https://www.prnewswire.com/news-releases/icecure-receives-notice-of-patent-allowance-in-china-for-a-novel-cryogen-flow-control-to-optimize-patient-cryoablation-outcomes-302633981.html
0 · Reply
MrTicker
MrTicker Dec. 5 at 1:31 PM
$ICCM IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes PR NEWSWIRE 7:30 AM ET 12/5/2025
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 5 at 1:03 PM
🚀 New Signal ✅ 💊 $ICCM 🗓️ Dec 5, 2025 💵 Entry: $0.6910 🎯 Target (Opt.): $0.8212 (+18.84%) 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
BinaryLogic
BinaryLogic Dec. 5 at 11:35 AM
$ICCM [Again]
0 · Reply
moneygrabber55
moneygrabber55 Dec. 4 at 9:09 PM
$ICCM is this a real company?
0 · Reply
Leemarvin70
Leemarvin70 Dec. 4 at 5:47 PM
$ICCM In the best-case scenario, it's a 10:1 risk-reward ratio, meaning a 28% drop followed by a 50% rise. When the bank runs out of money...it goes bankrupt.
1 · Reply
moneygrabber55
moneygrabber55 Dec. 4 at 3:54 PM
$ICCM price target?
0 · Reply
Joe_088
Joe_088 Dec. 4 at 11:49 AM
$ICCM In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Icecure Medical, with a price target of $3.00.
2 · Reply
Joe_088
Joe_088 Dec. 4 at 5:59 AM
0 · Reply
justme_DC
justme_DC Dec. 3 at 9:39 PM
$ICCM I hold. But just saying, over 30 days under $1. That means they had nothing material to present to get it over $1. We all know they will now get 180 days. Just saying that now that they will get a notice, and they knew that and could be fairly assumed, they had nothing to announce to avoid that notice.....we are in dead man's land for the next few months. Truth is, they received FDA marketing approval for over 70 yearse old, but their established book of business already available tanked. Short to mid term does not look good. Just saying, maybe better to have patience before getting in or averaging down until they have different material news. IE....they would have already presented it if they had it already. GL to all.
0 · Reply
Amb8675309
Amb8675309 Dec. 2 at 10:08 PM
$ICCM something is coming- folks at Maxim Are still not allowed to Discuss this ticker with retail- so wondering what’s going on?
0 · Reply
SuperBusa
SuperBusa Dec. 2 at 3:45 PM
0 · Reply
Joe_088
Joe_088 Dec. 2 at 1:06 PM
0 · Reply
BinaryLogic
BinaryLogic Nov. 30 at 11:15 AM
$ICCM [Again] Pull back 3YR on the Company and its SP. You will see a consistent support range $0.5-0.7 and a resistance $1.4. This allows a 100% movement in valuation, while the Company continues to develop its technology, broaden to other cancer treatments, secure IP and expand globally. Trade the consolidation pattern intermediate term and wait for breakout above $1.4 resistance if/where that occurs.
0 · Reply
SuperBusa
SuperBusa Nov. 28 at 4:10 PM
$ICCM Remember its a short day
1 · Reply
bert89
bert89 Nov. 28 at 3:48 PM
$SMX $ICCM Moon🚀🚀🚀🚀
0 · Reply